within Pharmacolibrary.Drugs.ATC.C;

model C07AB06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 6.666666666666667,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.0032,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004166666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Bevantolol is a non-selective beta-adrenergic blocker once used mainly for the management of hypertension and angina pectoris. It is a beta blocker with mild intrinsic sympathomimetic activity, but it is not widely marketed or available in many countries today and is not an approved or commonly prescribed medication currently.</p><h4>Pharmacokinetics</h4><p>Typical estimated pharmacokinetic parameters for an adult (assumed healthy) population based on class-related properties and limited available data; no direct clinical PK studies with detailed modeling found for bevantolol.</p><h4>References</h4><ol><li>J R Latts,Clinical pharmacokinetics and metabolism of bevantolol.,Angiology,1986<a href='https://pubmed.ncbi.nlm.nih.gov/2871781/'>https://pubmed.ncbi.nlm.nih.gov/2871781/</a></li><li>W H Frishman, R J Goldberg, P Benfield,Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.,Drugs,1988<a href='https://pubmed.ncbi.nlm.nih.gov/2894292/'>https://pubmed.ncbi.nlm.nih.gov/2894292/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C07AB06;
